Hubbry Logo
Sweat allergySweat allergyMain
Open search
Sweat allergy
Community hub
Sweat allergy
logo
7 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Sweat allergy
Sweat allergy
Sweat allergy
View on Wikipedia
from Wikipedia
Sweat allergy
SpecialtyDermatology
Causesincreases in the production of sweat.
TreatmentTannic acid, showering

A sweat allergy is the exacerbation of atopic dermatitis associated with an elevated body temperature and resulting increases in the production of sweat. It appears as small reddish welts that become visible in response to increased temperature and resulting production of sweat.[1] It can affect all ages. Sweating can trigger intense itching or cholinergic urticaria. The protein MGL_1304 secreted by mycobiota (fungi) present on the skin such as Malassezia globosa acts as a histamine or antigen. People can be desensitized using their own samples of sweat that have been purified that contains small amounts of the allergen.[2][3] The allergy is not due to the sweat itself but instead to an allergy-producing protein secreted by microorganisms found on the skin.[4]

Cholinergic urticaria (CU) is one of the physical urticaria (hives) which is provoked during sweating events such as exercise, bathing, staying in a heated environment, or emotional stress. The hives produced are typically smaller than classic hives and are generally shorter-lasting.[5][6]

Multiple subtypes have been elucidated, each of which require distinct treatment.[7][8]

Tannic acid has been found to suppress the allergic response, along with showering.[2]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Sweat allergy

View on Grokipedia
from Grokipedia
Sweat allergy, more accurately termed , is a form of chronic inducible urticaria in which small, punctate develop on the skin in response to an elevation in core body temperature, typically induced by sweating during physical exercise, exposure to , or emotional stress. This condition manifests as itchy or stinging wheals, often 1-3 mm in diameter, accompanied by surrounding , and episodes usually last 15-60 minutes before resolving spontaneously. Cholinergic urticaria affects up to 20% of young adults and accounts for approximately 7% of cases of chronic urticaria, with onset commonly occurring between ages 10 and 30. Although popularly called a "sweat allergy," it is not a true immunoglobulin E-mediated to sweat components in most cases; instead, it involves the release of or other mediators that irritate mast cells in the skin, leading to release and wheal formation. Subtypes include the conventional form, a follicular variant potentially linked to true sweat (e.g., to the MGL_1304 protein), and rarer presentations with anhidrosis or palpebral . In severe instances, symptoms can escalate to , systemic reactions, or even , significantly impairing quality of life. Diagnosis typically relies on patient history and provocation tests, such as exercise challenges or intradermal injections, to elicit the characteristic response, while ruling out other urticaria forms. Cholinergic urticaria has no known cure. Management focuses on avoiding triggers (such as hot environments, spicy foods, intense exercise, and emotional stress) and symptom control with second-generation H1-antihistamines as first-line therapy, often up-dosed beyond standard doses, with options like for refractory cases or autologous sweat desensitization in allergy-associated subtypes. Many individuals experience over time, with about 15% achieving complete resolution.

Definition and classification

Definition

Sweat allergy, commonly referred to as (CholU), is a subtype of chronic inducible urticaria characterized by the onset of small, pinpoint-sized (wheals) accompanied by intense itching or stinging, provoked by an elevation in core body temperature that induces sweating. This condition manifests as recurrent episodes of punctate wheals, typically 1-3 mm in diameter, surrounded by erythematous flares, occurring in response to physical or emotional stimuli that raise , such as exercise, hot baths, or stress. Unlike broader urticaria, which encompasses various forms of hive formation due to mediator release, cholinergic urticaria specifically ties its inducible nature to cholinergic pathways activated during thermoregulatory sweating. Despite its colloquial name, sweat allergy is not a genuine (IgE)-mediated to sweat components, such as proteins or electrolytes, but rather a non-allergic, exaggerated immune reaction involving the of cutaneous mast cells and subsequent liberation in response to nerve stimulation. This process is triggered by release from postganglionic sympathetic fibers, leading to localized inflammatory responses rather than systemic allergic sensitization. The condition was first documented in 1924 by Walter W. Duke, who termed it "urticaria calorica" to describe heat- and exertion-induced , distinguishing it from other thermal urticarias. The designation "" emerged later, reflecting its inducibility by cholinergic agonists like , which mimic the physiological activation. Within the urticaria spectrum, it is classified as a form of chronic inducible urticaria (CIndU), elicited by identifiable physical triggers, in contrast to (CSU), which arises without evident provocation.

Subtypes

Cholinergic urticaria, commonly referred to as sweat allergy, encompasses several subtypes distinguished by their underlying mechanisms and clinical presentations. The sweat-hypersensitivity subtype involves an IgE-mediated reaction to autologous sweat antigens, triggering release from and mast cells. This subtype is confirmed through positive skin prick tests using the patient's own sweat, which induce wheal-and-flare reactions indicative of immediate allergic response. In contrast, the anhidrosis or subtype is characterized by impaired sweating due to reduced (AChE) activity and decreased expression of the cholinergic muscarinic receptor M3 (CHRM3) in eccrine sweat glands, leading to acetylcholine overflow and paradoxical urticaria from gland dysfunction. This variant often presents without evidence of sweat allergy and is associated with acquired generalized anhidrosis. The follicular subtype features wheals centered on hair follicles, with positive autologous serum skin tests but negative autologous sweat skin tests, implicating serum factors alongside in activation, without true sweat . The palpebral angioedema subtype is a severe form linked to sweat allergy, with positive autologous sweat tests, predominantly affecting females with atopic backgrounds, and carrying a risk of . Rare mixed forms combine with other inducible urticarias, such as or urticaria, where multiple physical stimuli provoke overlapping wheal responses, complicating and .

Clinical features

Symptoms

The primary symptom of sweat allergy, medically termed , is an intense itching known as pruritus, often accompanied by stinging, burning, tingling, and warmth sensations that arise within minutes of exposure to a triggering factor such as increased body temperature. This discomfort is frequently described by patients as a "pins and needles" feeling, which can intensify rapidly and affect areas of the body where sweating occurs. In addition to these localized sensory experiences, patients may report systemic effects, including , , gastrointestinal upset such as and increased salivation, or anxiety-like symptoms attributable to activation. These broader manifestations highlight the condition's potential to disrupt daily activities beyond mere skin sensations. Symptoms generally peak between 15 and 30 minutes following the trigger's onset and persist for 30 minutes to 2 hours, though repeated episodes in quick succession may lead to refractoriness, where the response diminishes. Severity varies widely: mild cases involve primarily local discomfort, while severe instances can escalate to anaphylactoid reactions featuring or a sensation of swelling. These subjective experiences are often accompanied by visible small pinpoint hives (typically 1-4 mm in diameter), as described in the physical signs section. In some patients, symptoms exhibit a seasonal pattern, occurring primarily or exclusively in winter and often being more severe during this season due to lack of heat acclimatization, which results in stronger reactions to sudden increases in body temperature. In summer, symptoms may improve or disappear with better acclimatization. This seasonal variation is not universal but has been reported in several studies.

Physical signs

The physical signs of sweat allergy, also known as , primarily manifest as distinctive dermatological lesions triggered by sweating or increases in body temperature. These lesions typically present as small, punctate wheals or papules measuring 1-5 mm in diameter, surrounded by an erythematous flare that gives the appearance of tiny raised spots on reddened , often likened to "rice grains" scattered over the affected area. The wheals are non-pitting, evanescent, and blanch under pressure, distinguishing them from other edematous skin conditions. These lesions commonly appear on the upper body, including the chest, back, arms, , and upper trunk, while typically sparing the palms, soles, and sometimes the face. In milder cases, the distribution remains localized to these areas, but severe episodes may lead to generalization across the trunk and limbs. The lesions emerge rapidly, usually 2-20 minutes following exposure to a trigger such as exercise or heat, and resolve spontaneously within 15-60 minutes without leaving scars or residual pigmentation. Associated findings are generally limited to superficial skin changes, with rare instances of deeper affecting subcutaneous tissues. Vesicles or bullae are not observed, maintaining the characteristic punctate and urticarial nature of the eruption. These objective signs often accompany subjective sensations of itching, though the visible manifestations are the primary focus for clinical examination.

Pathophysiology

Triggers

Sweat allergy, also known as , is primarily triggered by factors that elevate core body temperature and induce sweating. Physical activities such as exercise, hot baths or showers, saunas, and exposure to warm environments are common precipitants, as they lead to and subsequent episodes. These triggers often involve an increase in core body temperature of as little as 0.5–1°C, which suffices to activate the response in susceptible individuals. Emotional and physiological stressors, including anxiety, emotional stress, and sexual activity, can also provoke episodes by stimulating activation without significant external . Such triggers mimic the physiological effects of by promoting internal temperature fluctuations and sweating through responses. Dietary factors like consumption of spicy foods, hot beverages, or alcohol frequently induce flushing, elevated body temperature, and , thereby eliciting symptoms. These substances act as vasodilators or thermogenic agents, contributing to the response in affected individuals. Other triggers encompass fever due to illness or passive heat exposure, where even mild systemic elevations can precipitate reactions; the precise threshold for these varies among patients but generally aligns with the 0.5–1°C increase observed in physical triggers.

Mechanisms

The primary mechanism in sweat allergy, or , centers on the pathway, where elevated levels of (ACh) act as a key mediator. ACh binds to M3 muscarinic receptors on eccrine sweat glands, promoting sweat , and can lead to of nearby mast cells through stimulation. This releases inflammatory mediators, including and , which initiate the characteristic urticarial response. The process is triggered by physiological stimuli that increase body or tone, leading to localized ACh accumulation in the skin. Histamine, liberated from mast cells, plays a central role in the downstream effects by binding to H1 receptors on endings and endothelial cells. This binding induces , increased causing , and activation of pruriceptive pathways that manifest as intense itching. Unlike typical allergic reactions, sweat allergy does not rely on IgE-mediated to external environmental allergens; instead, the response is predominantly non-IgE-mediated and driven by the direct pharmacological effects of ACh on resident cells. Tryptase further amplifies inflammation by promoting additional activation and contributing to wheal formation. Subtype-specific variations highlight distinct immunological underpinnings. In the sweat-hypersensitivity subtype, autologous sweat contains antigens, such as MGL_1304 from , that provoke an IgE-dependent reaction, leading to and activation upon sweat leakage into the , often due to partial duct obstruction. Conversely, the anhidrotic subtype involves reduced (AchE) activity, resulting in ACh buildup that irritates eccrine ducts and elicits a response without full sweating. These mechanisms underscore the interplay between sweat production anomalies and immune activation. Genetic and regulatory factors contribute to susceptibility, with strong associations to atopic diathesis observed in a majority of patients, suggesting shared pathways with other allergic conditions. No single causative gene has been identified, and while (HLA) linkages are not firmly established for this condition, dysregulation appears integral, potentially exacerbating hypersensitivity through impaired innervation or sweating control.

Epidemiology

Prevalence and incidence

Cholinergic urticaria, commonly referred to as sweat allergy, has a reported in the general population ranging from 0.02% to 11.2%, with higher estimates observed in specific cohorts such as medical students (4%) and chronic urticaria patients (up to 11%). In young adults, can reach up to 20%, though the condition is often underdiagnosed due to the mild nature of symptoms in many cases, leading to underreporting in epidemiological data. Incidence peaks during adolescence and early adulthood, typically between ages 10 and 30 years, with mean onset ages reported around 16 to 28 years; it is rare in children under 10 and the elderly. Annual new case rates are not well-tracked globally, reflecting challenges in for inducible urticarias. Geographic variation shows similar underlying occurrence across regions, but reports are more frequent from temperate climates with episodic exposure; for example, was 11.2% in the general population of young adults in compared to 0.7% among patients with chronic urticaria in , potentially reflecting differences in study populations, climate, or underdiagnosis in tropical areas. Underreporting is significant, with estimates suggesting that only a minority of affected individuals seek medical care—potentially as few as half or less in broader urticaria populations—further skewing data due to self-management of mild episodes.

Risk factors

Sweat allergy, clinically known as , predominantly affects young adults, with the highest prevalence observed in individuals aged 16 to 35 years and a typical onset following . It exhibits variable sex distribution across studies, with male predominance reported in several cohorts (-to-female ratios ranging from 1.5:1 to 3.3:1, particularly among those in their late teens and early twenties), though some studies show female predominance or no clear difference. A significant association exists with , where 15-57% of affected individuals have a personal history of atopic conditions such as , eczema (), or in various studies, reflecting an underlying predisposition in the . Lifestyle factors can influence susceptibility and episode frequency; individuals residing in hot or humid climates face heightened risk due to increased sweating triggers, while sedentary lifestyles may indirectly contribute by limiting to physical exertion. Comorbidities further elevate risk, including primary , which amplifies sweating and thus urticarial responses; anxiety disorders, as emotional stress serves as a common precipitant; and other cholinergic syndromes involving autonomic dysregulation. Family history of urticaria or related conditions is noted in 6-37% of cases in various studies, suggesting a potential genetic component.

Diagnosis

Clinical diagnosis

The clinical diagnosis of sweat allergy, also known as , begins with a detailed patient to identify characteristic episodic triggered specifically by increases in body temperature, such as those induced by heat, sweating, or exercise. Patients typically report small, pinpoint wheals accompanied by itching or stinging that appear within minutes of the trigger and resolve within 15-60 minutes, often without associated systemic allergic reactions like . The also involves inquiring about the absence of spontaneous triggers and excluding patterns suggestive of other urticaria subtypes, such as chronic spontaneous urticaria without identifiable provocations. During the , clinicians may attempt to reproduce symptoms through mild provocation, such as moderate exercise on a or application of a warm cloth to the , to elicit the characteristic small wheals (1-3 in diameter) surrounded by erythematous flares. These signs, when observed, confirm the link to stimuli and align with descriptions of transient punctate wheals detailed in clinical features. The examination focuses on the specificity of the response to thermal or exertional triggers rather than generalized skin changes. Differential diagnosis requires careful consideration to distinguish sweat allergy from conditions with overlapping presentations, ruling out spontaneous urticaria (which lacks consistent triggers), (induced by water contact regardless of temperature), and (typically involving irritant or allergic exposures without sweating). This differentiation relies on the history of trigger specificity and the absence of responses to non-cholinergic stimuli. Diagnostic criteria for sweat allergy follow the EAACI/GA²LEN guidelines for chronic inducible urticaria, emphasizing reproducible symptoms and signs elicited by provocation, such as a rise in core body temperature, without requiring advanced testing at this stage. Confirmation is based on the clinical reproducibility of in response to heat or exercise, establishing the inducible nature of the condition.

Diagnostic tests

Diagnosis of sweat allergy, also known as , relies on objective provocation and laboratory assessments following clinical suspicion of heat- or exercise-induced symptoms. Provocation tests aim to reproducibly elicit urticarial reactions under controlled conditions. The exercise challenge involves running or stationary for 15 to 30 minutes at moderate intensity to raise core body temperature and induce sweating, with a positive result defined by the appearance of characteristic 1- to 3-mm satellite wheals surrounded by flares within 5 to 30 minutes of symptom onset. Alternatively, of (0.02% solution, 0.05 mL) into the simulates cholinergic stimulation, producing localized wheals in approximately 50% of affected individuals if the diameter exceeds 3 mm compared to saline controls. These tests confirm mediation but require monitoring for potential severe reactions. Sweat-specific tests evaluate to autologous sweat or assess function. The autologous sweat skin prick test collects the patient's own sweat via exercise or , dilutes it (typically 1:10 to 1:100), and applies it via prick to the ; a positive response is indicated by a wheal greater than 3 mm in diameter at 15 to 20 minutes, suggesting an IgE-mediated mechanism in the sweat allergy subtype. The thermoregulatory sweat test, performed by applying iodine-starch powder to the skin followed by thermal exposure (e.g., in a heated chamber at 45-50°C), maps anhidrotic areas through color change where sweat is absent, helping identify associated in up to 20-30% of cases. Laboratory evaluations support subtype differentiation and exclusion of mimics. Serum total IgE levels are often elevated (>100 IU/mL) in atopic patients with sweat hypersensitivity, correlating with positive autologous sweat tests and clinical severity. Baseline serum is typically normal (<11.4 ng/mL), which helps rule out systemic , though acute elevations post-provocation may occur due to mast cell degranulation. is infrequently performed but may reveal perivascular lymphocytic and infiltrates around eccrine glands without . These tests have limitations, including false-negative results in mild or non-reproducible cases due to variable sweat production or threshold sensitivity, and they should be avoided in patients at high risk for , where passive heating alternatives like warm baths (42°C for 15 minutes) may be safer.

Treatment

Cholinergic urticaria (also known as sweat allergy) has no known cure, but symptoms can be effectively managed through trigger avoidance, lifestyle modifications, and pharmacological treatments. In some cases, symptoms may improve or resolve spontaneously over time.

First-line therapies

The first-line management of sweat allergy, also known as , emphasizes non-invasive strategies to prevent symptoms and minimize exposure to triggers such as , hot environments, intense exercise, spicy foods, and stress. modifications form the cornerstone of initial , focusing on environmental adjustments to reduce sweating and body temperature elevation. Patients are advised to maintain a cool environment, such as using or fans, and to wear loose, breathable made from natural fibers like to facilitate heat dissipation and avoid irritation. Additionally, avoidance of hot baths, spicy foods, intense exercise, emotional stress, and other precipitating factors is recommended, as these can precipitate episodes. For those wishing to incorporate physical activity, a gradual exercise desensitization program—beginning with short sessions of low-intensity exercise, such as walking for 5-10 minutes in a controlled cool setting, and progressively increasing duration and intensity over weeks—can help build tolerance and reduce reactivity over time, with some patients achieving symptom improvement after consistent application. Pharmacologic intervention begins with second-generation H1-antihistamines, which are recommended as the primary due to their efficacy in blocking histamine-mediated and wheal formation without significant . Common agents include at 10 mg daily, at 180 mg daily, or at 10 mg daily, administered consistently rather than as needed for optimal control. This aligns with international guidelines for chronic urticaria, which recommend a stepwise approach starting with second-generation H1-antihistamines up to fourfold dosing, applicable to inducible forms like . If symptoms persist at standard doses, up-dosing to four times the recommended amount (e.g., up to 40 mg daily, divided into twice-daily doses) is safe and guideline-supported, often improving response rates. These therapies provide symptomatic control in many patients with mild cases, though response rates are generally lower in compared to spontaneous forms, with up-dosing benefiting less than 50% of refractory cases. For acute itch relief during episodes, topical agents provide adjunctive support without systemic effects. Calamine lotion, applied as a thin layer to affected areas, soothes pruritus by its drying and cooling properties, offering temporary relief from the stinging sensation associated with wheals. Menthol-containing creams, such as those with 0.5-1% menthol in an aqueous base, can similarly alleviate discomfort through a mild anesthetic action on the skin. Post-episode, cool compresses—using a clean cloth soaked in cold water and applied for 10-15 minutes—help constrict blood vessels, reduce inflammation, and interrupt the itch-scratch cycle. Patient education plays a vital role in empowering individuals to manage their condition proactively. Maintaining a trigger diary, where patients log activities, environmental factors, diet, and symptom onset, enables identification of personal patterns and tailored avoidance strategies. Adequate hydration, aiming for 2-3 liters of water daily, supports and may lessen sweat-induced flares by stabilizing body temperature. For non-responders to these approaches, referral for advanced treatments is indicated.

Advanced treatments

For patients with persistent sweat allergy, often termed , who do not respond adequately to first-line therapies, advanced treatments target underlying immune pathways and activation. Immunomodulators represent a key escalation strategy, particularly biologics that inhibit IgE-mediated or cytokine-driven responses. , an anti-IgE administered subcutaneously at 300 mg monthly, has demonstrated variable efficacy in refractory cases, with response rates of approximately 30-60% in clinical studies for , and randomized trials showing significant reduction in urticaria symptoms and improved . , an IL-4 and IL-13 inhibitor approved in April 2025 for (CSU) in patients aged 12 years and older, has shown promise in case reports of , achieving complete resolution within months in treatment-resistant pediatric patients. Other agents focus on stabilization and adrenergic modulation for overlapping symptoms. Anticholinergics such as scopolamine butylbromide or oxybutynin reduce sweating and have shown efficacy in some refractory cases. Beta-blockers such as , dosed at 20-40 mg orally prior to known triggers, effectively mitigate episodes in cases with adrenergic components by blocking sweat-induced histamine release. , an attenuated , stabilizes mast cells and reduces wheal formation in double-blind studies of patients, though its use is limited by potential side effects like androgenic effects. Zileuton, a 5-lipoxygenase inhibitor, provides mast cell stabilization through inhibition, with supporting its role in chronic urticaria subsets including types. Phototherapy, particularly narrow-band ultraviolet B (NB-UVB), may be beneficial for patients with recalcitrant symptoms. Additionally, sweat desensitization involving intradermal injections of autologous sweat has induced tolerance in resistant patients via rapid desensitization protocols, leading to symptom remission in clinical studies. Emerging therapies as of 2025 offer novel oral options for the spectrum. Bruton tyrosine kinase (BTK) inhibitors, such as remibrutinib—an oral agent FDA-approved in September 2025 for (CSU) in adults—inhibit degranulation and show rapid symptom reduction in phase 3 trials, with potential extension to inducible forms like . Clinical trials for C5aR inhibitors, including INF904, report positive phase 2a data in urticaria, demonstrating reductions in urticaria activity scores and ongoing evaluation for broader application. In rare cases where exacerbates episodes, injections provide targeted relief by inhibiting sweat gland release, with reports of concurrent improvement following axillary treatments.

Prognosis

Natural course

The natural course of sweat allergy, also known as , is characterized by recurrent episodes triggered by sweating or increases in core body temperature, with individual acute attacks typically self-resolving within 15 to 30 minutes after the stimulus subsides. The condition is classified as chronic when symptoms recur for more than 6 weeks, distinguishing it from transient acute urticaria. In chronic cases, the overall disease duration varies widely, with a mean of approximately 4.9 years reported in clinical cohorts, though the median time to 50% remission can be as short as 34 months in some populations. Over time, the frequency of episodes often diminishes, particularly as patients experience to triggers such as exercise or emotional stress, leading to fewer and less severe flares. Following an episode, a refractory period lasting 24 to 48 hours commonly occurs, during which subsequent exposures to heat or sweat are less likely to provoke symptoms. This pattern contributes to a gradual reduction in episode intensity, especially in the early years of the disease. Spontaneous remission is a key feature, with approximately 35% to 50% of patients achieving resolution without specific intervention within 5 years, and up to 68% by 13 years from onset. This remission rate is higher than in some other forms of physical urticaria, reflecting the relatively benign progression in many cases. The condition typically emerges in or early adulthood, between the ages of 10 and 30 years, and often improves or fully resolves by ages 40 to 50, with rare persistence into older age.

Complications

Cholinergic urticaria can lead to severe systemic complications, most notably , which may occur in response to triggers like exercise or heat exposure. This life-threatening reaction involves widespread , , and potential airway compromise, as documented in clinical cases where patients experienced . , characterized by deeper tissue swelling often affecting the face or eyelids, accompanies anaphylactic episodes in up to 46% of certain subtypes, such as with positive autologous serum skin testing. Respiratory complications are common in severe flares, including dyspnea, wheezing, bronchospasm, and , which can impair lung function as evidenced by reduced forced expiratory volumes and increased residual volume during attacks. Cardiovascular effects, such as low and a weak, rapid , further heighten risks during these episodes, potentially leading to or fainting. Additional complications include intense stinging pain and headaches, which can significantly disrupt daily activities and , particularly in subtypes associated with anhidrosis or atopic conditions. Aspirin may exacerbate symptoms in over half of affected individuals, complicating management. Long-term, repeated episodes may contribute to acquired , though most cases remain otherwise benign without permanent organ damage.

References

  1. https://my.clevelandclinic.org/health/diseases/cholinergic-urticaria
  2. https://pmc.ncbi.nlm.nih.gov/articles/PMC9476404/
  3. https://dermnetnz.org/topics/cholinergic-urticaria
  4. https://acaai.org/allergies/allergic-conditions/skin-allergy/hives/
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC7273400/
  6. https://www.uptodate.com/contents/physical-inducible-urticaria
  7. https://emedicine.medscape.com/article/1049978-overview
  8. https://pmc.ncbi.nlm.nih.gov/articles/PMC8863185/
  9. https://pubmed.ncbi.nlm.nih.gov/32975301/
  10. https://www.jacionline.org/article/S0091-6749(05)01352-7/fulltext
  11. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.955161/full
  12. https://emedicine.medscape.com/article/1049978-differential
  13. https://emedicine.medscape.com/article/1049978-clinical
  14. https://www.webmd.com/allergies/cholinergic-urticaria-facts
  15. https://pubmed.ncbi.nlm.nih.gov/7247588/
  16. https://ijdvl.com/is-cholinergic-urticaria-a-seasonal-disorder-in-some-patients/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC4037671/
  18. https://www.aafp.org/pubs/afp/issues/2001/1015/p1367.html
  19. https://www.cancertherapyadvisor.com/home/decision-support-in-medicine/dermatology/physical-urticarias-adrenergic-urticaria-cholinergic-urticaria-pressure-urticaria-dermographism/
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC3710039/
  21. https://www.annallergy.org/article/S1081-1206%2819%2930191-7/fulltext
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC4336875/
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC6751347/
  24. https://www.sciencedirect.com/topics/nursing-and-health-professions/cholinergic-urticaria
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC9637282/
  26. https://journal.hep.com.cn/1560-9588/EN/10.17816/dv72329
  27. https://pubmed.ncbi.nlm.nih.gov/27584968/
  28. https://www.sciencedirect.com/science/article/pii/S1323893015302549
  29. https://pubmed.ncbi.nlm.nih.gov/27324252/
  30. https://www.medigraphic.com/cgi-bin/new/resumenI.cgi?IDARTICULO=114847
  31. https://onlinelibrary.wiley.com/doi/10.1155/2020/7301652
  32. https://www.sciencedirect.com/science/article/pii/S1323893024000856
  33. https://www.nature.com/articles/s41572-022-00389-z
  34. https://www.novartis.com/news/media-releases/novartis-real-world-study-shows-almost-half-chronic-urticaria-patients-are-not-receiving-any-treatment-despite-significant-disease-burden
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC8163939/
  36. https://www.kjim.org/journal/view.php?number=170063
  37. https://ijdvl.com/cholinergic-urticaria-clinicoepidemiological-paradigms-from-a-tertiary-care-center-in-north-india/
  38. https://anndermatol.org/pdf/10.5021/ad.2014.26.2.189
  39. https://www.medicalnewstoday.com/articles/320916
  40. https://pmc.ncbi.nlm.nih.gov/articles/PMC6627267/
  41. https://journals.lww.com/ejdv/fulltext/2021/41010/prevalence_of_cholinergic_urticaria_among_egyptian.8.aspx
  42. https://onlinelibrary.wiley.com/doi/10.1111/all.15090
  43. https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/Practice%20and%20Parameters/Urticaria-2014.pdf
  44. https://www.bsaci.org/wp-content/uploads/2020/01/Urticaria_Angioedema2015-1.pdf
  45. https://pubmed.ncbi.nlm.nih.gov/7520273/
  46. https://karger.com/iaa/article/170/2/84/167831/Immediate-Wheal-Reactivity-to-Autologous-Sweat-in
  47. https://emedicine.medscape.com/article/2093911-overview
  48. https://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2009.02177.x
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC4923395/
  50. https://www.jacionline.org/article/S0091-6749(22)01341-0/fulltext
  51. https://www.aafp.org/pubs/afp/issues/2016/0901/p352.html
  52. https://pmc.ncbi.nlm.nih.gov/articles/PMC10027330/
  53. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0023931
  54. https://www.jacionline.org/article/S0091-6749%2816%2930530-9/fulltext
  55. https://pmc.ncbi.nlm.nih.gov/articles/PMC2807703/
  56. https://www.aad.org/public/diseases/a-z/hives-self-care
  57. https://pubmed.ncbi.nlm.nih.gov/20674825/
  58. https://www.sciencedirect.com/science/article/abs/pii/S1081120610006137
  59. https://parkwoodskinclinic.com/cholinergic-urticaria/
  60. https://emedicine.medscape.com/article/1049978-treatment
  61. https://pubmed.ncbi.nlm.nih.gov/30654196/
  62. https://onlinelibrary.wiley.com/doi/10.1111/all.16334
  63. https://www.sanofi.com/en/media-room/press-releases/2025/2025-04-18-15-15-00-3064131
  64. https://pubmed.ncbi.nlm.nih.gov/41168088/
  65. https://pubmed.ncbi.nlm.nih.gov/25571938/
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC3651152/
  67. https://pubmed.ncbi.nlm.nih.gov/3555598/
  68. https://pubmed.ncbi.nlm.nih.gov/16681569/
  69. https://pubmed.ncbi.nlm.nih.gov/21364312/
  70. https://www.ajmc.com/view/fda-approves-remibrutinib-for-chronic-spontaneous-urticaria
  71. https://www.nejm.org/doi/abs/10.1056/NEJMoa2408792
  72. https://www.dermatologytimes.com/view/oral-c5ar-inhibitor-inf904-shows-early-efficacy-in-hs-and-csu-phase-2a-trials
  73. https://pubmed.ncbi.nlm.nih.gov/23301956/
  74. https://www.sciencedirect.com/science/article/abs/pii/S0377123704800157
  75. https://www.jaci-inpractice.org/article/S2213-2198(15)00566-8/fulltext
Add your contribution
Related Hubs
User Avatar
No comments yet.